Intellia Therapeutics, Inc. (NTLA)
USD 8.84
(2.31%)
USD 8.84
(2.31%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 551.56 Million USD | 8.09% |
| 2022 | 510.28 Million USD | 69.58% |
| 2021 | 300.9 Million USD | 54.64% |
| 2020 | 194.57 Million USD | 30.18% |
| 2019 | 149.47 Million USD | 23.22% |
| 2018 | 121.3 Million USD | 26.79% |
| 2017 | 95.67 Million USD | 96.7% |
| 2016 | 48.63 Million USD | 150.03% |
| 2015 | 19.45 Million USD | 53.77% |
| 2014 | 12.65 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 140.42 Million USD | 1.78% |
| 2024 Q2 | 143.4 Million USD | 2.12% |
| 2023 FY | 551.56 Million USD | 8.09% |
| 2023 Q4 | 137.97 Million USD | -3.58% |
| 2023 Q2 | 145.92 Million USD | 17.15% |
| 2023 Q1 | 124.56 Million USD | 0.73% |
| 2023 Q3 | 143.09 Million USD | -1.94% |
| 2022 Q2 | 112.33 Million USD | -27.76% |
| 2022 Q4 | 123.66 Million USD | 4.09% |
| 2022 FY | 510.28 Million USD | 69.58% |
| 2022 Q1 | 155.49 Million USD | 66.72% |
| 2022 Q3 | 118.79 Million USD | 5.76% |
| 2021 Q1 | 52.87 Million USD | 7.91% |
| 2021 FY | 300.9 Million USD | 54.64% |
| 2021 Q4 | 93.26 Million USD | 17.77% |
| 2021 Q3 | 79.19 Million USD | 4.8% |
| 2021 Q2 | 75.56 Million USD | 42.93% |
| 2020 Q3 | 50.32 Million USD | 2.08% |
| 2020 Q2 | 49.29 Million USD | 7.25% |
| 2020 Q1 | 45.96 Million USD | 12.91% |
| 2020 Q4 | 48.99 Million USD | -2.64% |
| 2020 FY | 194.57 Million USD | 30.18% |
| 2019 Q4 | 40.7 Million USD | 13.25% |
| 2019 FY | 149.47 Million USD | 23.22% |
| 2019 Q1 | 34.24 Million USD | 19.62% |
| 2019 Q2 | 38.57 Million USD | 12.66% |
| 2019 Q3 | 35.94 Million USD | -6.83% |
| 2018 Q1 | 29.89 Million USD | -4.73% |
| 2018 FY | 121.3 Million USD | 26.79% |
| 2018 Q4 | 28.62 Million USD | -9.14% |
| 2018 Q3 | 31.5 Million USD | 0.75% |
| 2018 Q2 | 31.27 Million USD | 4.59% |
| 2017 Q3 | 23.19 Million USD | 5.74% |
| 2017 FY | 95.67 Million USD | 96.7% |
| 2017 Q4 | 31.38 Million USD | 35.32% |
| 2017 Q1 | 19.16 Million USD | 16.5% |
| 2017 Q2 | 21.93 Million USD | 14.46% |
| 2016 Q1 | 8.47 Million USD | 17.91% |
| 2016 Q2 | 11.15 Million USD | 31.65% |
| 2016 FY | 48.63 Million USD | 150.03% |
| 2016 Q4 | 16.44 Million USD | 30.9% |
| 2016 Q3 | 12.56 Million USD | 12.68% |
| 2015 Q3 | 4.98 Million USD | 3.96% |
| 2015 FY | 19.45 Million USD | 53.77% |
| 2015 Q4 | 7.18 Million USD | 44.0% |
| 2015 Q1 | 2.48 Million USD | -56.79% |
| 2015 Q2 | 4.79 Million USD | 93.43% |
| 2014 Q2 | 166.99 Thousand USD | 0.0% |
| 2014 Q4 | 5.74 Million USD | 0.0% |
| 2014 FY | 12.65 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -5262.82% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -19945.392% |
| XOMA Corporation | 46.46 Million USD | -1087.108% |
| Mesoblast Limited | 5.9 Million USD | -9245.408% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -227.463% |
| Aptorum Group Limited | 10.56 Thousand USD | -5220096.858% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -8948.582% |
| HilleVax, Inc. | 133.34 Million USD | -313.638% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -112.419% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3865.35% |
| Precision BioSciences, Inc. | 92.46 Million USD | -496.526% |
| Dyadic International, Inc. | 9.15 Million USD | -5926.268% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -6530.196% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -249.504% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -2378.614% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1758.251% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -373.638% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -71.423% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -320.423% |
| IGM Biosciences, Inc. | 265.59 Million USD | -107.675% |
| Opthea Limited | 191.96 Million USD | -187.323% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -788.219% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -2974.675% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -354.312% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -554.111% |
| NextCure, Inc. | 67.63 Million USD | -715.48% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -8093.265% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -824.312% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1073.395% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -125.125% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1692.486% |
| Senti Biosciences, Inc. | 94.7 Million USD | -482.404% |
| Apollomics, Inc. | 54.14 Million USD | -918.777% |
| PureTech Health plc | 144.59 Million USD | -281.451% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -4227.365% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -551.077% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -125.939% |
| ChromaDex Corporation | 56.37 Million USD | -878.318% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -6145.627% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -174.254% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -141.196% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -6758.648% |
| Gritstone bio, Inc. | 148.37 Million USD | -271.74% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -3415.446% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -117.114% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -220.861% |
| Fortress Biotech, Inc. | 200.19 Million USD | -175.514% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -955.609% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1657.867% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -123.181% |
| Celcuity Inc. | 66.23 Million USD | -732.8% |
| ContextLogic Inc. | 387 Million USD | -42.524% |
| GH Research PLC | 41.22 Million USD | -1238.038% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1584.377% |
| Cassava Sciences, Inc. | 105.95 Million USD | -420.556% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -2031.821% |
| ImmuCell Corporation | 9.61 Million USD | -5635.107% |
| Amarin Corporation plc | 272.35 Million USD | -102.516% |
| TG Therapeutics, Inc. | 198.47 Million USD | -177.902% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -412.98% |
| Acelyrin, Inc. | 422.06 Million USD | -30.683% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1554.86% |
| Seer, Inc. | 110.49 Million USD | -399.2% |
| Novavax, Inc. | 779.12 Million USD | 29.207% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -228.652% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 83.058% |
| AnaptysBio, Inc. | 181.56 Million USD | -203.779% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1809.987% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -588.322% |
| AbCellera Biologics Inc. | 275.23 Million USD | -100.4% |
| CorMedix Inc. | 48.95 Million USD | -1026.615% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -397.502% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -2982.664% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 80.408% |
| Aptose Biosciences Inc. | 52.35 Million USD | -953.491% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -3727.562% |
| Soligenix, Inc. | 7.79 Million USD | -6975.667% |
| Century Therapeutics, Inc. | 56.07 Million USD | -883.692% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -23.742% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -2740.413% |
| Kura Oncology, Inc. | 165.8 Million USD | -232.661% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -334.092% |
| Ardelyx, Inc. | 169.93 Million USD | -224.571% |
| Ainos, Inc. | 12.95 Million USD | -4158.321% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -381.688% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -22125.876% |
| Prothena Corporation plc | 282.4 Million USD | -95.31% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -412.141% |
| Autolus Therapeutics plc | 196.72 Million USD | -180.373% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -551.53% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -175.753% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -2745.617% |
| Celularity Inc. | 215.05 Million USD | -156.473% |
| Rallybio Corporation | 78.93 Million USD | -598.786% |
| GRI Bio, Inc. | 11.33 Million USD | -4768.191% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -7717.31% |
| Omeros Corporation | 94.75 Million USD | -482.122% |
| INmune Bio, Inc. | 29.89 Million USD | -1744.949% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -219.648% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1268.164% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -3351.74% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -3403.886% |
| Humacyte, Inc. | 23.49 Million USD | -2247.389% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -100.065% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -82.97% |
| Immunocore Holdings plc | 308.04 Million USD | -79.057% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -16170.383% |
| Verastem, Inc. | 92.08 Million USD | -498.981% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -196.98% |
| Histogen Inc. | 14.27 Million USD | -3764.672% |
| Surrozen, Inc. | 18.55 Million USD | -2873.402% |
| Blueprint Medicines Corporation | 722.86 Million USD | 23.697% |
| Organovo Holdings, Inc. | 14.91 Million USD | -3598.062% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -10735.765% |
| IO Biotech, Inc. | 91.44 Million USD | -503.18% |
| MEI Pharma, Inc. | 34.78 Million USD | -1485.643% |
| GT Biopharma, Inc. | 13.57 Million USD | -3962.802% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -209.632% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1038.471% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -638.77% |
| Summit Therapeutics Inc. | 87.68 Million USD | -529.024% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1771.682% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -243.569% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -3489.388% |
| Turnstone Biologics Corp. | 78.33 Million USD | -604.085% |
| Pulmatrix, Inc. | 22.03 Million USD | -2402.795% |
| Synaptogenix, Inc. | 8.31 Million USD | -6534.3% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -3681.475% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -117.962% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -520.672% |
| Cytokinetics, Incorporated | 173.61 Million USD | -217.7% |
| Exelixis, Inc. | 1.58 Billion USD | 65.24% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -137.693% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 35.505% |
| Evogene Ltd. | 27.79 Million USD | -1884.764% |
| Replimune Group, Inc. | 234.77 Million USD | -134.936% |
| PDS Biotechnology Corporation | 43.04 Million USD | -1181.364% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -7070.419% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -700.985% |
| ESSA Pharma Inc. | 32.13 Million USD | -1616.451% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -3271.385% |
| BioLineRx Ltd. | 50.8 Million USD | -985.717% |
| Avid Bioservices, Inc. | 25.99 Million USD | -2021.734% |
| Insmed Incorporated | 949.26 Million USD | 41.895% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1518.207% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -118.397% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1584.685% |
| MediWound Ltd. | 18.86 Million USD | -2823.288% |
| MiMedx Group, Inc. | 229.72 Million USD | -140.096% |
| OmniAb, Inc. | 83.89 Million USD | -557.448% |
| Alector, Inc. | 248.8 Million USD | -121.689% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -135.402% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 57.955% |
| Mereo BioPharma Group plc | 35.84 Million USD | -1438.882% |
| Zai Lab Limited | 547.47 Million USD | -0.747% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -38.357% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -139.859% |
| Aura Biosciences, Inc. | 84.99 Million USD | -548.97% |
| Immunic, Inc. | 99.22 Million USD | -455.885% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -127.767% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -246.871% |
| Veracyte, Inc. | 357.93 Million USD | -54.098% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 93.882% |
| FibroGen, Inc. | 398.11 Million USD | -38.545% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3781.534% |
| Allakos Inc. | 196.05 Million USD | -181.331% |
| scPharmaceuticals Inc. | 65.17 Million USD | -746.246% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -386.094% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -49.633% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -7907.698% |
| NLS Pharmaceutics AG | 11.8 Million USD | -4571.492% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -7640.482% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -74.247% |
| Precigen, Inc. | 84.18 Million USD | -555.214% |
| Fortrea Holdings Inc. | 457.3 Million USD | -20.614% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -916.187% |
| Incyte Corporation | 1.19 Billion USD | 53.669% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -5450.269% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -287.164% |
| XBiotech Inc. | 37.51 Million USD | -1370.451% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -432.112% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -700.985% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -2169.202% |
| CRISPR Therapeutics AG | 463.49 Million USD | -19.002% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -219.064% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1374.46% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -2571.151% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -288.26% |
| Agenus Inc. | 78.18 Million USD | -605.481% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -4282.065% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -456.716% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -398.181% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 42.44% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1812.172% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -8097.178% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -28.081% |
| UroGen Pharma Ltd. | 138.88 Million USD | -297.13% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -2372.468% |
| Sutro Biopharma, Inc. | 243 Million USD | -126.973% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -9872.359% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -2045.503% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -2066.487% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -346.421% |
| Chimerix, Inc. | 93.38 Million USD | -490.611% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -564.113% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -938.215% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -11079.774% |
| Pluri Inc. | 22.48 Million USD | -2353.585% |
| Cue Biopharma, Inc. | 19.54 Million USD | -2722.464% |
| MeiraGTx Holdings plc | 151.07 Million USD | -265.087% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -3336.946% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -7126.22% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -534.969% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -6425.295% |
| CalciMedica, Inc. | 21.81 Million USD | -2428.148% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -221.998% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -87.01% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1495.274% |
| NLS Pharmaceutics AG | 11.8 Million USD | -4571.492% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -660.246% |
| Nutriband Inc. | 5.73 Million USD | -9519.167% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -1164.683% |
| Vor Biopharma Inc. | 126.03 Million USD | -337.626% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 53.618% |
| ProKidney Corp. | 151.52 Million USD | -264.017% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -643.601% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1541.106% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 10.202% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -7292.655% |
| Bicycle Therapeutics plc | 216.92 Million USD | -154.269% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -266.003% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1348.744% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -10.586% |
| Atai Life Sciences N.V. | 125.78 Million USD | -338.499% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -575.613% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -577.525% |
| MediciNova, Inc. | 10.9 Million USD | -4960.116% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -328.168% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -7497.826% |
| GeoVax Labs, Inc. | 6.02 Million USD | -9058.92% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -258.971% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -15.788% |
| Biomea Fusion, Inc. | 126.13 Million USD | -337.282% |
| RenovoRx, Inc. | 11.39 Million USD | -4739.996% |
| Erasca, Inc. | 141.52 Million USD | -289.73% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -188.644% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1899.732% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -312.88% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -110.483% |
| bluebird bio, Inc. | 240.23 Million USD | -129.597% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -165.184% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -660.089% |
| Imunon, Inc. | 20.31 Million USD | -2615.679% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 68.415% |
| BioAtla, Inc. | 129.68 Million USD | -325.306% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -549.528% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -1220.863% |
| DBV Technologies S.A. | 92.16 Million USD | -498.487% |
| Fortress Biotech, Inc. | 200.19 Million USD | -175.514% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -124.984% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -396.142% |
| aTyr Pharma, Inc. | 12.97 Million USD | -4149.68% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -116.501% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -6606.121% |
| Galecto, Inc. | 35.62 Million USD | -1448.169% |
| Akari Therapeutics, Plc | 16.8 Million USD | -3181.959% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -24155.641% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -84.274% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -219.066% |
| Entera Bio Ltd. | 8.86 Million USD | -6125.35% |
| Travere Therapeutics, Inc. | 472 Million USD | -16.857% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1388.145% |
| Xencor, Inc. | 306.97 Million USD | -79.677% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -919.908% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -788.448% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -2591.894% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -187.58% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -8097.178% |
| Portage Biotech Inc. | 18.19 Million USD | -2930.749% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -7497.826% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -425.496% |
| OncoCyte Corporation | 25.63 Million USD | -2051.445% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -4714.201% |
| Purple Biotech Ltd. | -22.46 Million USD | 2555.005% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -3246.881% |
| Onconetix, Inc. | 34.9 Million USD | -1480.082% |
| MacroGenics, Inc. | 217.21 Million USD | -153.926% |
| Tharimmune, Inc. | 9.45 Million USD | -5733.455% |
| Genprex, Inc. | 31.06 Million USD | -1675.776% |
| Apogee Therapeutics, Inc. | 93 Million USD | -493.063% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -194.128% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1763.021% |
| Prime Medicine, Inc. | 186.63 Million USD | -195.526% |
| Aditxt, Inc. | 25.95 Million USD | -2025.433% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -72000.131% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -10026.202% |
| OKYO Pharma Limited | 8243.57 USD | -6690763.303% |
| Savara Inc. | 15.74 Million USD | -3403.118% |
| Curis, Inc. | 58.35 Million USD | -845.191% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -10730.973% |
| Adagene Inc. | 41.83 Million USD | -1218.547% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1941.174% |
| BeiGene, Ltd. | 3.28 Billion USD | 83.218% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -150.906% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1304.001% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -220.958% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -12083.989% |
| SciSparc Ltd. | 9.01 Million USD | -6021.03% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -12083.989% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -1194.482% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -6271.577% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -2288.911% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -3739.385% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -86.516% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -726.923% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 69.358% |
| ADMA Biologics, Inc. | 66.58 Million USD | -728.351% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -323.425% |
| Clene Inc. | 41.07 Million USD | -1242.892% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -1170.48% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -165.01% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -906.581% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -56.674% |
| Adicet Bio, Inc. | 152.03 Million USD | -262.782% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1535.336% |
| Absci Corporation | 73.66 Million USD | -648.739% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -7445.261% |
| Quantum-Si incorporated | 111.65 Million USD | -393.974% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -3683.611% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -1439.741% |
| Surrozen, Inc. | 18.55 Million USD | -2873.402% |
| Generation Bio Co. | 144.46 Million USD | -281.794% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -564.297% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -266.401% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -537.944% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -580.425% |
| Invivyd, Inc. | 205.75 Million USD | -168.069% |
| Cingulate Inc. | 22.75 Million USD | -2323.487% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -664.376% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -5781.173% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -6598.688% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -632.939% |
| Jaguar Health, Inc. | 42.01 Million USD | -1212.784% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -5261.777% |
| 2seventy bio, Inc. | 289.88 Million USD | -90.269% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1585.973% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -437.809% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 26.856% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -4206.456% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1401.595% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -431.876% |
| Kronos Bio, Inc. | 128.11 Million USD | -330.514% |
| Innoviva, Inc. | 132.15 Million USD | -317.366% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -556.064% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -317.3% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -223.921% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 28.155% |
| Evaxion Biotech A/S | 22.27 Million USD | -2376.722% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -306.928% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -134.827% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -589.932% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 7462.066% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1134.84% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -788.562% |
| Clearmind Medicine Inc. | 8.74 Million USD | -6209.849% |
| AlloVir, Inc. | 180.93 Million USD | -204.845% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -397.893% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -112.611% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -18705.62% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -447.042% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -225.836% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1356.511% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -143.387% |
| ImmunityBio, Inc. | 362.87 Million USD | -52.0% |
| Korro Bio, Inc. | 84.53 Million USD | -552.478% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -245.188% |
| Kineta, Inc. | 21.15 Million USD | -2507.137% |
| Lantern Pharma Inc. | 17.87 Million USD | -2985.24% |
| BioVie Inc. | 31.95 Million USD | -1626.33% |
| Codexis, Inc. | 66.51 Million USD | -729.198% |
| Celularity Inc. | 215.05 Million USD | -156.473% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -1182.712% |
| Virax Biolabs Group Limited | 6.54 Million USD | -8324.633% |
| Kodiak Sciences Inc. | 277.32 Million USD | -98.891% |
| Cibus, Inc. | 320.3 Million USD | -72.2% |
| Annexon, Inc. | 143.72 Million USD | -283.77% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -2307.639% |
| Moderna, Inc. | 6.39 Billion USD | 91.374% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 29.249% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -332.292% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -86082.188% |
| Immix Biopharma, Inc. | 16.14 Million USD | -3317.15% |
| Eyenovia, Inc. | 25.4 Million USD | -2070.969% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -293.091% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -284.873% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -204.227% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -9816.685% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -597.011% |
| Alkermes plc | 996.24 Million USD | 44.636% |
| Arcellx, Inc. | 200.19 Million USD | -175.509% |
| Moolec Science SA | 52.75 Million USD | -945.611% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1101.669% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1085.144% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -154.87% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -5439.48% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -486.323% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1037.883% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -5813.1% |
| Humacyte, Inc. | 23.49 Million USD | -2247.389% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -802.166% |
| Geron Corporation | 70.44 Million USD | -683.018% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -681.321% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -3693.439% |
| Royalty Pharma plc | 862.4 Million USD | 36.043% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -2337.48% |
| Notable Labs, Ltd. | 14.77 Million USD | -3634.367% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -165.416% |
| Structure Therapeutics Inc. | 102.77 Million USD | -436.673% |
| IN8bio, Inc. | 30.33 Million USD | -1718.13% |
| 89bio, Inc. | 151.2 Million USD | -264.783% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -2493.53% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -440.687% |
| Acasti Pharma Inc. | 11.3 Million USD | -4780.683% |
| Genelux Corporation | 24.33 Million USD | -2166.554% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1525.935% |
| Liquidia Corporation | 87.98 Million USD | -526.894% |
| Mustang Bio, Inc. | 48.5 Million USD | -1037.226% |
| Immunovant, Inc. | 282.7 Million USD | -95.1% |
| Vericel Corporation | 142.04 Million USD | -288.317% |
| Quantum-Si incorporated | 111.65 Million USD | -393.974% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -2346.62% |
| XOMA Corporation | 46.46 Million USD | -1087.108% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -716.53% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -2306.367% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -3351.74% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1645.869% |
| Vaxcyte, Inc. | 468.04 Million USD | -17.846% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1085.093% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -7445.261% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -3372.026% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1791.71% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1687.375% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -118.457% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -1232.8% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1776.394% |
| PepGen Inc. | 84.76 Million USD | -550.692% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1761.449% |
| United Therapeutics Corporation | 885.1 Million USD | 37.683% |
| Solid Biosciences Inc. | 104.31 Million USD | -428.75% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1585.43% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -9816.685% |
| Immuneering Corporation | 58.41 Million USD | -844.254% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -10735.765% |
| Silo Pharma, Inc. | 3.92 Million USD | -13963.902% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -13891.864% |
| Belite Bio, Inc | 31.66 Million USD | -1641.714% |
| Pharming Group N.V. | 225.49 Million USD | -144.607% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -2169.202% |
| Bionomics Limited | 17.89 Billion USD | 96.917% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -571.038% |
| uniQure N.V. | 285.08 Million USD | -93.474% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -3059.569% |
| GeoVax Labs, Inc. | 6.02 Million USD | -9058.92% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -184.009% |
| Altimmune, Inc. | 30.55 Million USD | -1705.099% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -6538.371% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1645.869% |
| Peak Bio, Inc. | 1249.13 USD | -44155912.585% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3781.534% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -6105.04% |
| Benitec Biopharma Inc. | 22.38 Million USD | -2364.328% |
| Zura Bio Limited | 62.63 Million USD | -780.561% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -28.976% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -4277595.052% |
| Compugen Ltd. | 43.97 Million USD | -1154.386% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -48514.113% |
| argenx SE | 1.53 Billion USD | 64.033% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -644.153% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -2308.901% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -126.805% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1832.404% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -44.96% |
| PolyPid Ltd. | 21.04 Million USD | -2520.889% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -3288.83% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -6355.595% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1598.328% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -981.502% |
| Instil Bio, Inc. | 85.78 Million USD | -542.963% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1113.7% |
| Immunome, Inc. | 122.82 Million USD | -349.085% |
| Verona Pharma plc | 67.15 Million USD | -721.378% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -3253.303% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -2030.833% |
| Shattuck Labs, Inc. | 93.61 Million USD | -489.192% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -680.117% |
| Design Therapeutics, Inc. | 78.19 Million USD | -605.418% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -533.685% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -4282.725% |
| Achilles Therapeutics plc | 75.25 Million USD | -632.929% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -984.074% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -734.454% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -919.095% |
| Beam Therapeutics Inc. | 554.19 Million USD | 0.474% |
| Moolec Science SA | 52.75 Million USD | -945.611% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -871.768% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1038.917% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -490.049% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -560.329% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -22.3% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -527.564% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -316.103% |
| Athira Pharma, Inc. | 125.46 Million USD | -339.614% |
| HCW Biologics Inc. | 21.02 Million USD | -2523.067% |
| XOMA Corporation | 46.46 Million USD | -1087.108% |
| NeurAxis, Inc. | 8.82 Million USD | -6152.733% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1326.525% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -2030.833% |
| 180 Life Sciences Corp. | 13.47 Million USD | -3992.495% |
| Nektar Therapeutics | 190.9 Million USD | -188.925% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1832.404% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1981.189% |
| Arvinas, Inc. | 480 Million USD | -14.91% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -18705.62% |
| Palisade Bio, Inc. | 13.32 Million USD | -4040.886% |
| Nutriband Inc. | 5.73 Million USD | -9519.167% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -24155.641% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -891.08% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1114.662% |
| Merus N.V. | 200.49 Million USD | -175.103% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -433.662% |
| Neurogene Inc. | 55.58 Million USD | -892.329% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -121.968% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -6426.636% |
| CervoMed Inc. | 14.95 Million USD | -3587.489% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -470.33% |
| Sesen Bio, Inc. | 78.38 Million USD | -603.699% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -1493.2% |
| Rezolute, Inc. | 70.38 Million USD | -683.619% |
| Clene Inc. | 41.07 Million USD | -1242.892% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -3267.628% |
| BeyondSpring Inc. | 24.86 Million USD | -2118.243% |
| Synlogic, Inc. | 58.53 Million USD | -842.332% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -2982.752% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -12178.851% |
| Peak Bio, Inc. | 1249.13 USD | -44155912.585% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -812.494% |
| Krystal Biotech, Inc. | 160.42 Million USD | -243.813% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -103.807% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -58.479% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -25474.132% |
| MannKind Corporation | 125.59 Million USD | -339.155% |
| Ikena Oncology, Inc. | 84.57 Million USD | -552.147% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -5617.487% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -515.58% |
| Gossamer Bio, Inc. | 183.75 Million USD | -200.157% |
| CohBar, Inc. | 12.38 Million USD | -4352.315% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -987.387% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1899.732% |
| Legend Biotech Corporation | 583.14 Million USD | 5.415% |
| Mural Oncology plc | 192.07 Million USD | -187.168% |
| Disc Medicine, Inc. | 91.12 Million USD | -505.285% |
| Champions Oncology, Inc. | 28.11 Million USD | -1862.17% |
| REGENXBIO Inc. | 321.15 Million USD | -71.743% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -10188.042% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -889.25% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1315.7% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -382.319% |
| Vaxart, Inc. | 90.72 Million USD | -507.947% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -6373.773% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -1188.884% |
| Cellectis S.A. | 97.32 Million USD | -466.755% |
| Longeveron Inc. | 21.25 Million USD | -2495.605% |
| Repare Therapeutics Inc. | 167.35 Million USD | -229.575% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 59.468% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -629.151% |
| Revolution Medicines, Inc. | 498.76 Million USD | -10.586% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -8191.732% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -1154.871% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -639.464% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -692.082% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -4887.034% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 88.449% |
| Denali Therapeutics Inc. | 527.23 Million USD | -4.616% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -6271.577% |
| Veru Inc. | 101.34 Million USD | -444.229% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -2256.415% |
| Cingulate Inc. | 22.75 Million USD | -2323.487% |
| Passage Bio, Inc. | 108.38 Million USD | -408.876% |
| Context Therapeutics Inc. | 25.07 Million USD | -2099.874% |
| Exicure, Inc. | 14.07 Million USD | -3818.485% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -167.667% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -1173.795% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -5910.118% |
| Nuvalent, Inc. | 149.49 Million USD | -268.96% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -6737.396% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -432.143% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -2471.523% |
| OmniAb, Inc. | 83.89 Million USD | -557.448% |
| Anew Medical, Inc. | 1.3 Million USD | -42300.724% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1583.451% |
| Lipocine Inc. | 15.08 Million USD | -3557.566% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -705.053% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -624.296% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1268.164% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -380.278% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -2364.108% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 16.951% |
| Ocugen, Inc. | 71.56 Million USD | -670.699% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -487.61% |
| Q32 Bio Inc. | 92.68 Million USD | -495.129% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -2504.921% |
| Alumis Inc. Common Stock | 158.17 Million USD | -248.708% |
| Equillium, Inc. | 50.6 Million USD | -989.922% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -783.835% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -3866.516% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -2823.736% |
| Dominari Holdings Inc. | 23.83 Million USD | -2214.101% |
| Edesa Biotech, Inc. | 9.22 Million USD | -5880.489% |
| vTv Therapeutics Inc. | 11.9 Million USD | -4532.284% |
| Bio-Techne Corporation | 563.03 Million USD | 2.038% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -34.921% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -105.229% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -316.978% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -3727.396% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -236.945% |
| Nkarta, Inc. | 131.65 Million USD | -318.964% |
| BioCardia, Inc. | 12.12 Million USD | -4450.499% |
| Iterum Therapeutics plc | 47.46 Million USD | -1061.974% |